ClinicalTrials.gg
Status unknownNCT06236945Updated Sep 26, 2024

HUTT to Assess Cardiac Autonomic Nervous Function

An observational study in Autonomic Nervous System Diseases, sponsored by The First Hospital of Hebei Medical University. Status unknown at 1 site in China. Open to participants aged 12 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-26.

Sponsored by The First Hospital of Hebei Medical University · Observational

The sponsor has not verified this record recently (last verified Sep 2024), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,122
Ages
12 Years to 85 Years
Sex
All
01

Study summary

Autonomic nervous system diseases can cause abnormalities in the circulatory system, leading to malignant arrhythmia and sudden cardiac death. Standardized, operable, and simplified diagnostic indicators are urgently needed to evaluate autonomic nervous function, particularly cardiac autonomic nervous function. The investigators use HUTT in order to provide data support for cardiac autonomic nervous system evaluation.

Read the detailed description

In this study, 169 samples with vertical tilt test and 24-h Holter ECG data from February 13, 2023 to October 31, 2023 were selected. The AC, DC, and 24-h HRV were compared with the CASS to identify the indicators with the strongest correlation with the CASS sympathetic and vagus nerve scores. The best index was selected, and the score intervals were delimited. The sensitivity and specificity of the defined vagal and sympathetic intervals were analyzed.

02

Conditions studied

  • Autonomic Nervous System Diseases
03

In context

Autonomic Nervous System Diseases

108 studies on the registry are indexed under Autonomic Nervous System Diseases; 29 are open to participants now.

This study's planned enrollment of 1,122 is above the median of 69 across 34 observational studies indexed under Autonomic Nervous System Diseases.

Browse Autonomic Nervous System Diseases studies →

Lead sponsor

The First Hospital of Hebei Medical University is the lead sponsor of 38 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

A total of 1122 (546 males, 576 females) samples were collected according to the inclusion and exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Vertical tilt test and 24-hour holter were performed at the same time

    • Receive treatment in our hospital.

Exclusion criteria

Exclusion Criteria:

  • Taking benzodiazepines or hypotensive drugs within 24 hours

    • Combined with mental illness, severe dementia, serious organ disease

      • Severe arrhythmia, deep breathing and poor coordination of Valsaval movements affected the interpretation of results.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,122 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. To find the indicators which are most correlated to the sympathetic and vagus nerves.

    The investigators use HUTT and CASS score to find some indicators which are most correlated to the sympathetic and vagus nerves,so that can give data support to the clinical treatments

    Time frame: February 13, 2023 to December 31, 2025

07

Study locations

1 of 1 sites recruiting
  • The First Hospital Of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Dec 2025, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2023
First posted
Feb 1, 2024
StartActual
Jan 31, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Sep 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06236945
Lead sponsor
The First Hospital of Hebei Medical University
Responsible party
Yan Ding (Head of Neurology, The First Hospital of Hebei Medical University) — Principal investigator
First posted
Feb 1, 2024
Start date
Jan 31, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Sep 26, 2024

Study contacts

Yan Ding, M.D.
Contact
dingding13001300@126.com
18633889260
Yan Ding, M.D.
principal investigator · Department of Neurology,Xuanwu Hospital,Capital Medical University,Beijing,China.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion